PROs and Equity Considerations

Angela M. Stover, PhD University of North Carolina at Chapel Hill







Disclosure

- Angela Stover, faculty for this educational event, was a paid consultant to Navigating Cancer in 2021 (<\$5k).
- She receives grant funding from NIH, PCORI, AHRQ, foundations, Sivan Innovation, UroGen Pharma Ltd., ASCO, and Pfizer Global.
- She has received speaking honoraria in the past 2 years from Henry Ford Cancer Center, Genentech, Pfizer, Association of Community Cancer Centers, Purchaser Business Group on Health (PBGH – PROMs).
- All of the relevant financial relationships listed for these individuals have been mitigated.



Learning Outcomes


Upon Completing this session, participants will be able to:

- 1. Identify barriers to PROM completion by historically underserved groups.
- 2. Describe PROM equity issues happening in health systems.
- 3. Describe solutions for improving equity for PROMs.



Defining Health Equity

A widely used definition of health inequity has been proposed by Whitehead (1992) and built upon by the WHO's Commission on Social Determinants of Health (CSDH) (4;5). It posits that health inequities are not merely differences in health status (termed "inequalities") but differences between groups that are unnecessary, avoidable, unfair, and unjust (6). The criteria of fairness and justice can be understood as systematic differences considered avoidable (5). Thus, all should have a "fair and just opportunity to be as healthy as possible" (7).





PROM Equity Issue: Example



- UNC Health clinics implemented clinic-wide PROMs in select clinics
 EHR integration, Best practice alerts for concerning responses
- Primary care: PHQ-2 and PHQ-9
- Compared demographic and clinical characteristics of patients completing at least one PROM vs. those who were missed (equity)



Epic@UNC PROM Workflow

ASSIGNMENT

Patient Identified



PROs automatically assigned

PRO COLLECTION



Patient completes
questionnaires on assigned
tablet after check-in
(kiosk or front desk)

Epic Hyperspace



Clinician collects questionnaire via "Answer Qnr" link, or Flowsheet

REVIEW

Symptom Review





Provider reviews PRO responses with patient





Patient completes questionnaires at home



Disparity in PROM Completion

Adults seen in the primary care clinic between 11/1/19 and 9/30/21

(n=8,762)

Completed at least 1 PROM

n=6,260 (71%)

- Women (59%)
- Age 18-64 (70%)
- White (71%)
- Non-Hispanic (92%)

Did not complete any PROMs n=2,502 (29%)

Higher odds:

- Medicaid (OR=1.9)
- Age 65+ (OR =1.4)
- Black/racism (OR=1.4)

Disparity in PROM Completion

Downstream implications for performance measures

Adults seen in the primary care clinic between 11/1/19 and 9/30/21

(n=8,762)

Completed at least 1 PROM

n=6,260 (71%)

- Women (59%)
- Age 18-64 (70%)
- White (71%)
- Non-Hispanic (92%)

Did not complete any PROMs

n=2,502 (29%)

Higher odds:

- Medicaid (OR=1.9)
- Age 65+ (OR =1.4)
- Black/racism (OR=1.4)

What Can We Do?



Nature Medicine 2022 Paper

Patient reported outcome assessment must be inclusive and equitable

Patient-reported outcomes are increasingly collected in clinical trials and in routine clinical practice, but strategies must be taken to include underserved groups to avoid increasing health disparities.

Melanie J. Calvert, Samantha Cruz Rivera, Ameeta Retzer, Sarah E. Hughes, Lisa Campbell, Barbara Molony-Oates, Olalekan Lee Aiyegbusi, Angela M. Stover, Roger Wilson, Christel McMullan, Nicola E. Anderson, Grace M. Turner, Elin Haf Davies, Rav Verdi, Galina Velikova, Paul Kamudoni, Syed Muslim, Adrian Gheorghe, Daniel O'Connor, Xiaoxuan Liu, Albert W. Wu and Alastair K. Denniston

atient-reported outcomes (PROs)
collected in clinical trials can provide
valuable evidence of the risks and
benefits of treatment from a patient
perspective, to inform regulatory approvals,
clinical guidelines and health policy. PROs
are increasingly collected routinely in
clinical settings, at an aggregate level for
audit and benchmarking, for real-world
evidence generation, and as an input or
predicted output for clinical decision tools

and artificial intelligence (AI) in health^{1,2}. At an individual patient level, PROs can be used to facilitate shared decision making, screen or monitor symptoms, and provide timely care tailored to individual needs³. PROs are also increasingly used in value-based healthcare initiatives⁴.

Efforts to capture and report PRO data should be inclusive and equitable, addressing the diverse needs of all patients with the condition of interest, including groups historically and currently underserved by research^{5,6}. Issues of diversity, equity and inclusion (Box 1) have recently been highlighted in PRO ethical guidelines, which have identified a number of concerns to be addressed in PROs research⁵.

Lack of representation

Underserved groups are often poorly represented in research and may receive suboptimal clinical care due to a range Predicting response to immunotheraty in melasema Boarling humaliporetic stem and microry vaccine-mediated prevention of fasteriolosis

1120

NATURE MEDICINE | VOL 28 | JUNE 2022 | 1110-1127 | www.nature.com/naturemedicine



Nature Medicine 2022 Paper

Patient-reported outcomes are increasingly collected in clinical trials and in routine clinical practice, but **strategies** must be taken to **include underserved groups** to avoid increasing health disparities

Recommendations derived from literature review and international expert consensus



Barriers to Equitable PROMs

burden








characteristics and symptom





Literacy, health literacy, digital exclusion





Actions to Promote Equitable PROMs



Include diverse patients & clinicians in PRO planning



Train clinicians to look for missing PROs in workflow



Address participant acceptability & concerns



Provide feedback mechanism to clinic on characteristics of patients they are missing



User-centered design to minimize barriers



If used in clinical care, review PROM responses with all patients



Minimize eligibility requirements (e.g., language)



Ongoing training and support for clinics



Provide alternative ways to complete PRO



Conclusions

- ✓ Representative patient populations are vital in PROs
- Downstream implications for assessing quality of care
- Targeted initiatives are necessary to avoid unintentionally exacerbating health inequality
- Build in equity from the beginning
- Seek input from representative patients throughout
- User-centered design to promote accessibility



References

- Benkhalti M, et al. Int J Tech Assess Health Care. 2021;37:E17.
- Calvert M, et al. Nature Med. 2022;28:1110-1127.
- Sisodia RC, et al. JAMIA. 2021;28(10):2265-2268.



Thank You!

Presenter(s) contact information:

- Name: Angela M. Stover, PhD
- Organization: University of North Carolina at Chapel Hill
- Email: stoveram@email.unc.edu
- Twitter: @Angela_M_Stover

